News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NuPathe Inc. (PATH) to Report Second Quarter 2012 Results and Hold Conference Call on Tuesday, August 14, 2012


8/10/2012 9:43:14 AM

CONSHOHOCKEN, PA--(Marketwire - August 09, 2012) - NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, will report second quarter 2012 results on Tuesday, August 14, 2012, before the open of the U.S. financial markets. NuPathe will also host a conference call at 8:30 a.m. EDT on the same day to discuss its second quarter 2012 financial results and recent operational highlights. A question-and-answer session will follow NuPathe's remarks.

To participate on the live call, please dial 800-753-0420 (domestic) or +1-913-312-0382 (international), and provide the participant passcode 9424985 five to ten minutes before the start of the call. A replay of the call will be available for 90 days within a few hours after the call ends. Investors may listen to the replay of the call by dialing 888-203-1112 (domestic) or +1-719-457-0820 (international), with the passcode 9424985.

A live audio webcast of the call will be also available via the "Investor Relations" page of the NuPathe website, www.nupathe.com. Please log on through NuPathe's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on NuPathe's website for 90 days following the call.

About NuPathe
NuPathe Inc. is a specialty pharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, NP101, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. NuPathe has resubmitted its migraine patch New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), and the Prescription Drug User Fee Act (PDUFA) date, the target date for the FDA to complete its review of the NDA, is January 17, 2013. In addition to NP101, NuPathe has two proprietary product candidates based on its LAD™, or Long-Acting Delivery, biodegradable implant technology that allows delivery of therapeutic levels of medication over a period of months with a single dose. NP201, for the continuous symptomatic treatment of Parkinson's disease, utilizes a leading FDA-approved dopamine agonist, ropinirole, and is being developed to provide up to two months of continuous delivery. NP202, for the long-term treatment of schizophrenia and bipolar disorder, is being developed to address the long-standing problem of patient noncompliance by providing three months of continuous delivery of risperidone, an atypical antipsychotic. NuPathe is actively seeking partnerships to maximize the commercial potential for our pipeline products in the U.S. and territories throughout the world.

For more information about NuPathe, please visit our website and our blog at www.nupathe.com. You can also follow us on StockTwits (stocktwits.nupathe.com), Twitter (twitter.nupathe.com), SlideShare (slideshare.nupathe.com) and LinkedIn (linkedin.nupathe.com).


Contact Information:

Investor Contacts
John Woolford
Westwicke Partners, LLC
(443) 213-0506
john.woolford@westwicke.com

Keith A. Goldan
Vice President & Chief Financial Officer
NuPathe Inc.
(484) 567-0130

Media Contact
Jennifer Guinan
Sage Strategic Marketing
(610) 410-8111
jennifer@sagestrat.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES